RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced preliminary results from a Phase 1 study assessing two new formulations of the opioid analgesic buprenorphine utilizing the company’s proprietary BEMA™ drug delivery technology. The study was performed to select the optimal formulation for Phase 2 clinical development of the product candidate, known as BEMA™ Buprenorphine.
